Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPOX | P50336 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RORA | P35398 | 1/20 | 0.31 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4365935 | 1.00 | PPOX (0.33) | PPOXKDM4ENPC1RORANR5A1 | |
| SCHEMBL2211157 | 0.88 | PPOX (0.36) | PPOXKDM4ENPC1RORANR5A1 | |
| SCHEMBL2211161 | 0.88 | PPOX (0.36) | PPOXKDM4ENPC1RORANR5A1 | |
| SCHEMBL2212119 | 0.87 | KDM4E (0.34) | PPOXKDM4ENPC1RORANR5A1 | |
| SCHEMBL2212121 | 0.87 | KDM4E (0.34) | PPOXKDM4ENPC1RORANR5A1 | |
| SCHEMBL2211058 | 0.77 | MEN1 (0.37) | KDM4EMEN1KMT2A | |
| SCHEMBL2210113 | 0.77 | KMT2A (0.43) | KDM4ERORANR5A1MEN1KMT2A | |
| SCHEMBL2210116 | 0.77 | KMT2A (0.43) | KDM4ERORANR5A1MEN1KMT2A | |
| SCHEMBL2211060 | 0.77 | MEN1 (0.37) | KDM4EMEN1KMT2A | |
| SCHEMBL2210803 | 0.77 | KMT2A (0.40) | KDM4ERORANR5A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625443-B2 | Chiral phosphanes for use in asymmetric syntheses | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-01 | — | — | US | disclosed |
| US-20050085377-A1 | Chiral phosphanes for use in asymmetric syntheses | LIGAND CHEMIE GMBH (DE) | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085377-A1 | Chiral phosphanes for use in asymmetric syntheses | PHOSPHO1, AGPS, GGPS1 | PPOX 173/4885KDM4E 3985/4885NPC1 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.